3405 related articles for article (PubMed ID: 23743292)
1. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
[TBL] [Abstract][Full Text] [Related]
2. Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease--resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2012 Nov; 53(9):1791-806. PubMed ID: 22967820
[TBL] [Abstract][Full Text] [Related]
3. Parkinson disease: from pathology to molecular disease mechanisms.
Dexter DT; Jenner P
Free Radic Biol Med; 2013 Sep; 62():132-144. PubMed ID: 23380027
[TBL] [Abstract][Full Text] [Related]
4. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease.
Zuo L; Motherwell MS
Gene; 2013 Dec; 532(1):18-23. PubMed ID: 23954870
[TBL] [Abstract][Full Text] [Related]
5. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease.
Büeler H
Exp Neurol; 2009 Aug; 218(2):235-46. PubMed ID: 19303005
[TBL] [Abstract][Full Text] [Related]
6. Decreased expression of serum- and glucocorticoid-inducible kinase 1 (SGK1) promotes alpha-synuclein increase related with down-regulation of dopaminergic cell in the Substantia Nigra of chronic MPTP-induced Parkinsonism mice and in SH-SY5Y cells.
Yeo S; Sung B; Hong YM; van den Noort M; Bosch P; Lee SH; Song J; Park SK; Lim S
Gene; 2018 Jun; 661():189-195. PubMed ID: 29604467
[TBL] [Abstract][Full Text] [Related]
7. Targeted Overexpression of α-Synuclein by rAAV2/1 Vectors Induces Progressive Nigrostriatal Degeneration and Increases Vulnerability to MPTP in Mouse.
Song LK; Ma KL; Yuan YH; Mu Z; Song XY; Niu F; Han N; Chen NH
PLoS One; 2015; 10(6):e0131281. PubMed ID: 26114655
[TBL] [Abstract][Full Text] [Related]
8. Calpain activation and progression of inflammatory cycles in Parkinson's disease.
Gao A; McCoy HM; Zaman V; Shields DC; Banik NL; Haque A
Front Biosci (Landmark Ed); 2022 Jan; 27(1):20. PubMed ID: 35090325
[TBL] [Abstract][Full Text] [Related]
9. Oxidative damage to macromolecules in human Parkinson disease and the rotenone model.
Sanders LH; Timothy Greenamyre J
Free Radic Biol Med; 2013 Sep; 62():111-120. PubMed ID: 23328732
[TBL] [Abstract][Full Text] [Related]
10. Alpha-synuclein aggregation, Ubiquitin proteasome system impairment, and L-Dopa response in zinc-induced Parkinsonism: resemblance to sporadic Parkinson's disease.
Kumar V; Singh D; Singh BK; Singh S; Mittra N; Jha RR; Patel DK; Singh C
Mol Cell Biochem; 2018 Jul; 444(1-2):149-160. PubMed ID: 29198021
[TBL] [Abstract][Full Text] [Related]
11. A split-GFP tool reveals differences in the sub-mitochondrial distribution of wt and mutant alpha-synuclein.
Vicario M; Cieri D; Vallese F; Catoni C; Barazzuol L; Berto P; Grinzato A; Barbieri L; Brini M; Calì T
Cell Death Dis; 2019 Nov; 10(11):857. PubMed ID: 31719530
[TBL] [Abstract][Full Text] [Related]
12. The deglycase activity of DJ-1 mitigates α-synuclein glycation and aggregation in dopaminergic cells: Role of oxidative stress mediated downregulation of DJ-1 in Parkinson's disease.
Sharma N; Rao SP; Kalivendi SV
Free Radic Biol Med; 2019 May; 135():28-37. PubMed ID: 30796974
[TBL] [Abstract][Full Text] [Related]
13. Common Mechanisms Underlying α-Synuclein-Induced Mitochondrial Dysfunction in Parkinson's Disease.
Sohrabi T; Mirzaei-Behbahani B; Zadali R; Pirhaghi M; Morozova-Roche LA; Meratan AA
J Mol Biol; 2023 Jun; 435(12):167992. PubMed ID: 36736886
[TBL] [Abstract][Full Text] [Related]
14. α-Synuclein and mitochondrial bioenergetics regulate tetrahydrobiopterin levels in a human dopaminergic model of Parkinson disease.
Ryan BJ; Lourenço-Venda LL; Crabtree MJ; Hale AB; Channon KM; Wade-Martins R
Free Radic Biol Med; 2014 Feb; 67():58-68. PubMed ID: 24148766
[TBL] [Abstract][Full Text] [Related]
15. Genes Implicated in Familial Parkinson's Disease Provide a Dual Picture of Nigral Dopaminergic Neurodegeneration with Mitochondria Taking Center Stage.
Franco R; Rivas-Santisteban R; Navarro G; Pinna A; Reyes-Resina I
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33924963
[TBL] [Abstract][Full Text] [Related]
16. The Overcrowded Crossroads: Mitochondria, Alpha-Synuclein, and the Endo-Lysosomal System Interaction in Parkinson's Disease.
Lin KJ; Lin KL; Chen SD; Liou CW; Chuang YC; Lin HY; Lin TK
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31731450
[TBL] [Abstract][Full Text] [Related]
17. Physiological and pathological role of alpha-synuclein in Parkinson's disease through iron mediated oxidative stress; the role of a putative iron-responsive element.
Olivares D; Huang X; Branden L; Greig NH; Rogers JT
Int J Mol Sci; 2009 Mar; 10(3):1226-60. PubMed ID: 19399246
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease.
Yan MH; Wang X; Zhu X
Free Radic Biol Med; 2013 Sep; 62():90-101. PubMed ID: 23200807
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective effects of osmotin in Parkinson's disease-associated pathology via the AdipoR1/MAPK/AMPK/mTOR signaling pathways.
Park JS; Choe K; Lee HJ; Park TJ; Kim MO
J Biomed Sci; 2023 Aug; 30(1):66. PubMed ID: 37568205
[TBL] [Abstract][Full Text] [Related]
20. Mutant α-Synuclein Overexpression Induces Stressless Pacemaking in Vagal Motoneurons at Risk in Parkinson's Disease.
Lasser-Katz E; Simchovitz A; Chiu WH; Oertel WH; Sharon R; Soreq H; Roeper J; Goldberg JA
J Neurosci; 2017 Jan; 37(1):47-57. PubMed ID: 28053029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
